The Psychedelic Therapies Executive Order
JAMA · 04.08.2026 · 336 (5) · 367
DOI: 10.1001/jama.2026.11892 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 04.08.2026. Verfasst von I Glenn Cohen und 2 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Law School, Cambridge, Massachusetts. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
This Viewpoint discusses the executive order supporting the development and approval of psychedelic drugs and outlines issues surrounding their ethical and evidence-based integration into clinical care.
Autor:innen und Institutionen
- Harvard Law School, Cambridge, Massachusetts.
- The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics, Harvard University, Cambridge, Massachusetts.
- Perelman School of Medicine, University of Pennsylvania, Philadelphia.
- Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas.
Zitieren
APA
Cohen, I. G., Lynch, H. F., & McGuire, A. L. (2026). The Psychedelic Therapies Executive Order. JAMA, 336(5), 367. https://doi.org/10.1001/jama.2026.11892
Vancouver
Cohen IG, Lynch HF, McGuire AL. The Psychedelic Therapies Executive Order. JAMA. 2026;336(5):367. doi:10.1001/jama.2026.11892
BibTeX
@article{Cohen2026,
author = {Cohen, I Glenn and Lynch, Holly Fernandez and McGuire, Amy L},
title = {The Psychedelic Therapies Executive Order},
journal = {JAMA},
year = {2026},
volume = {336},
number = {5},
pages = {367},
doi = {10.1001/jama.2026.11892}
}
EUVIMED